Halozyme Therapeutics, Inc. (HALO) Misses Q1 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.19 -0.51%
EPS Growth %: +23.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
PMCB, CULP, HURC, More
EPS Growth %: +23.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 EPS of ($0.14), $0.03 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $7.31 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- SoundHound AI completes LivePerson acquisition, names new CFO
- CIENA (CIEN) PT Lowered to $394 at UBS on Group Multiple Compression
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
